MicroRNA 204 mediated negative regulation of the IGF2R promotes breast cancer progression and is a potential mechanism driving breast cancer disparity

In the US, African American women have a significantly higher rate of mortality due to breast cancer compared to Caucasian American women. Molecular differences in tumor biology exist between racial groups; however, their contribution to cancer disparity is not well understood. Our studies have identified a race-specific, mechanistic link between microRNA-204 and the IGF2R. The IGF2R is a tumor suppressor gene in several cancers including breast cancer and IGF2R levels are found at significantly lower levels in African American women with breast cancer when compared to their Caucasian counterparts. We observed elevated levels of miR-204 in serum of African American women with breast cancer when compared to Caucasian American women and identified IGF2R as a direct target of miR-204. We show mechanistically that miR-204 mediated inhibition of IGF2R leads to activation of the IGF1R signaling pathway resulting in increased proliferation, migration and invasion, processes that are required for tumor progression. We developed a unique doxycycline-inducible miR-204 transgenic mouse model to define in vivo the oncogenic potential of miR-204 and the mechanism and functional consequences of IGF2R loss. We observed a significant increase in tumor growth and increased metastasis in these animals when compared to non-transgenic controls. This is the first characterization of miR-204 in an in vivo model. These data support a mechanism whereby miR-204 promotes tumor aggression through the IGF2-mediated hyperactivation of the IGF1R signaling pathway in response to direct negative regulation of the tumor suppressor IGF2R and that this could be a potential mechanism promoting breast cancer disparity.

[1]  Runsheng Li,et al.  A dual yet opposite growth-regulating function of miR-204 and its target XRN1 in prostate adenocarcinoma cells and neuroendocrine-like prostate cancer cells , 2015, Oncotarget.

[2]  T. Ma,et al.  miR‐204 functions as a tumor suppressor by regulating SIX1 in NSCLC , 2014, FEBS letters.

[3]  Lei Ma,et al.  Decreased expression of miR-204 is associated with poor prognosis in patients with breast cancer. , 2014, International journal of clinical and experimental pathology.

[4]  N. Selvamurugan,et al.  Regulation of Breast Cancer and Bone Metastasis by MicroRNAs , 2013, Disease markers.

[5]  H. Selby,et al.  Overcoming IGF1R/IR Resistance through Inhibition of MEK Signaling in Colorectal Cancer Models , 2013, Clinical Cancer Research.

[6]  Lourdes M. Nogueira,et al.  MicroRNA-510 promotes cell and tumor growth by targeting peroxiredoxin1 in breast cancer , 2013, Breast Cancer Research.

[7]  Han Liu,et al.  PUMA and BIM Are Required for Oncogene Inactivation–Induced Apoptosis , 2013, Science Signaling.

[8]  Jueheng Wu,et al.  Loss of miR-204 expression enhances glioma migration and stem cell-like phenotype. , 2013, Cancer research.

[9]  A. Pertsemlidis,et al.  Genomic Loss of Tumor Suppressor miRNA-204 Promotes Cancer Cell Migration and Invasion by Activating AKT/mTOR/Rac1 Signaling and Actin Reorganization , 2012, PloS one.

[10]  R. Berkowitz,et al.  Dysregulation of microRNA‐204 mediates migration and invasion of endometrial cancer by regulating FOXC1 , 2012, International journal of cancer.

[11]  D. Epstein,et al.  Role of miR-204 in the regulation of apoptosis, endoplasmic reticulum stress response, and inflammation in human trabecular meshwork cells. , 2011, Investigative ophthalmology & visual science.

[12]  E. Paquet,et al.  The Journal of Experimental Medicine CORRESPONDENCE , 2005 .

[13]  Jun Yu,et al.  A microRNA contribution to aberrant Ras activation in gastric cancer. , 2011, American journal of translational research.

[14]  Douglas Hanahan,et al.  Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy , 2010, Proceedings of the National Academy of Sciences.

[15]  Dawn L Hershman,et al.  Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group. , 2009, Journal of the National Cancer Institute.

[16]  David P Turner,et al.  MicroRNA-mediated inhibition of prostate-derived Ets factor messenger RNA translation affects prostate-derived Ets factor regulatory networks in human breast cancer. , 2008, Cancer research.

[17]  Manfred Kunz,et al.  MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth , 2008, Cell Research.

[18]  Adrian V. Lee,et al.  Oncogenic Transformation by the Signaling Adaptor Proteins Insulin Receptor Substrate (IRS)-1 and IRS-2 , 2007, Cell cycle.

[19]  Adrian V. Lee,et al.  Constitutively Active Type I Insulin-Like Growth Factor Receptor Causes Transformation and Xenograft Growth of Immortalized Mammary Epithelial Cells and Is Accompanied by an Epithelial-to-Mesenchymal Transition Mediated by NF-κB and Snail , 2007, Molecular and Cellular Biology.

[20]  D. Macphee,et al.  A Dose-Dependent Decrease in the Fraction of Cases Harboring M6P/IGF2R Mutations in Hepatocellular Carcinomas from the Atomic Bomb Survivors , 2006, Radiation research.

[21]  T. Mak,et al.  FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal , 2006, The Journal of experimental medicine.

[22]  C. Benz,et al.  Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies , 2006, Molecular Cancer.

[23]  Brandy M Heckman,et al.  P190-B Rho GTPase-activating protein overexpression disrupts ductal morphogenesis and induces hyperplastic lesions in the developing mammary gland. , 2006, Molecular endocrinology.

[24]  H. Kuniyasu,et al.  Alterations of the M6p/Igf2 receptor gene in hepatocellular carcinomas induced by N‐nitrosodiethylamine and a choline‐deficient L‐amino acid–defined diet in rats , 2004, Molecular carcinogenesis.

[25]  C. Roberts,et al.  The insulin-like growth factor system and cancer. , 2003, Cancer letters.

[26]  Zhihong Chen,et al.  Decreased expression of the mannose 6- phosphate/insulin-like growth factor-II receptor promotes growth of human breast cancer cells , 2002, BMC Cancer.

[27]  Robert B Boxer,et al.  A novel doxycycline‐inducible system for the transgenic analysis of mammary gland biology , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  W. Isaacs,et al.  DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. , 1999, Cancer research.

[29]  A. Costantino,et al.  Insulin Receptor Isoform A, a Newly Recognized, High-Affinity Insulin-Like Growth Factor II Receptor in Fetal and Cancer Cells , 1999, Molecular and Cellular Biology.

[30]  M. Ellis,et al.  The mannose 6-phosphate/insulin-like growth factor 2 receptor (M6P/IGF2R), a putative breast tumor suppressor gene , 1998, Breast Cancer Research and Treatment.

[31]  A. Leaf,et al.  Mannose-6-phosphate/insulin-like growth factor-II receptor is a receptor for retinoic acid. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  T. Walsh,et al.  Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. , 1997, British Journal of Cancer.

[33]  E. Diamandis,et al.  Associations between insulin-like growth factors and their binding proteins and other prognostic indicators in breast cancer. , 1996, British Journal of Cancer.

[34]  R. Bentley,et al.  M6P/IGF2 receptor: a candidate breast tumor suppressor gene. , 1996, Oncogene.

[35]  D. Rifkin,et al.  Cellular activation of latent transforming growth factor beta requires binding to the cation-independent mannose 6-phosphate/insulin-like growth factor type II receptor. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[36]  M. Czech,et al.  Direct demonstration of rapid insulin-like growth factor II Receptor internalization and recycling in rat adipocytes. Insulin stimulates 125I-insulin-like growth factor II degradation by modulating the IGF-II receptor recycling process. , 1985, The Journal of biological chemistry.

[37]  M. Anscher,et al.  Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.

[38]  T. Barrette,et al.  ONCOMINE: a cancer microarray database and integrated data-mining platform. , 2004, Neoplasia.